| Literature DB >> 35029746 |
Carsten Framme1, Bernd Junker2, Nicolas Feltgen3, Hans Hoerauf3, Nina-Antonia Striebe3, Joachim Wachtlin4,5, Ingo Volkmann2.
Abstract
Intravitreal injection (IVI) of drugs for treatment of various macular diseases is now one of the most frequently performed surgical procedures worldwide. As mostly chronic diseases are treated, the indications for treatment often mean a continuous treatment over years with a corresponding effort regarding spatial, personnel and financial resources. The diagnosis and indications for treatment are nowadays mainly made by spectral domain optical coherence tomography (SD-OCT). The ability to clinically assess and evaluate a fluorescence angiography is less practiced, although these are still a component of the indications for intravitreal injections. Therefore, it can happen that despite all diligence patients may receive anti-vascular endothelial growth factor (VEGF) treatment, sometimes permanently, based on a misinterpretation of the macular diagnosis or disease activity and these indications, once made, are rarely questioned or retracted. Therefore, the aim of this manuscript is to point out possible and typical misinterpretations in the indications or continuation of IVI treatment with anti-VEGF by means of case studies and to sensitize for differential diagnoses.Entities:
Keywords: Age-related macular degeneration; Central serous chorioretinopathy; Intravitreal injections; Macular telangiectasis; Retinal macroaneurysm
Mesh:
Substances:
Year: 2022 PMID: 35029746 DOI: 10.1007/s00347-021-01553-8
Source DB: PubMed Journal: Ophthalmologe ISSN: 0941-293X Impact factor: 1.059